Majláth Zsófia, Vécsei László
Department of Neurology, University of Szeged, Semmelweis utca 6, H-6725 Szeged, Hungary.
Neurodegener Dis Manag. 2014;4(1):23-30. doi: 10.2217/nmt.13.77.
Oral levodopa is the current baseline therapy in the management of Parkinson's disease, but nonmotor complications and therapy-related dyskinesias pose an important challenge for clinicians. Glutamate receptors have been implicated in the neurodegenerative process of Parkinson's disease and also in the development of levodopa-induced dyskinesias. This article discusses the role of NMDA receptors in Parkinson's disease and their modulation as a possible therapeutic approach.
口服左旋多巴是目前帕金森病治疗的基础疗法，但非运动并发症和与治疗相关的运动障碍给临床医生带来了重大挑战。谷氨酸受体已被证明与帕金森病的神经退行性过程以及左旋多巴诱导的运动障碍的发生有关。本文讨论了N-甲基-D-天冬氨酸受体在帕金森病中的作用及其作为一种可能的治疗方法的调节作用。
